中国癌痛治疗十年回顾  

TREATMENT OF CANCER PAIN IN CHINA OVER THE LAST DECADE

作　　者：赵雩卿[1] 刘端祺[1] 战淑珺[1] 

机构地区：[1]北京军区总医院肿瘤科全军肿瘤内科诊疗中心,北京100700

出　　处：《中国药物依赖性杂志》2008年第4期252-254,共3页Chinese Journal of Drug Dependence

摘　　要：目的:通过文献复习,回顾总结我国10a癌痛治疗现状。方法:对中文生物医学期刊文献数据库(CMCC)、中国生物医学文献数据库(CBMdisc)及中国期刊全文数据库(CJFD)进行联合检索。结果:口服阿片类药物的临床研究报告占27.3%,阿片类药物直肠给药占7.4%,芬太尼贴剂治疗癌痛研究占25.6%,中药、介入及其他癌痛治疗手段占39.7%;其中,口服阿片类药物主要是吗啡控缓释制剂(美施康定和美菲康)。结论:尽管癌痛治疗在我国已经受到多方关注,并取得了长足的进展,但仍存在用药简单,用药量不足,向基层医生和患者普及宣传不够,理论研究薄弱等问题。Objective：To review the clinical research of past 10 years, and sum up the present situation of cancer pain management in China. Methods ： Literatures were collected through the retrieval of several related medical databases including CMCC, CBMdisc, CJFD. Results： From 1997 -2006, the clinical research report on oral opiates accounts for 27.3%, the opiates rectal administration accounts for 7. 4%, Fentanyl transdermal patch account for 25.6%, the traditional Chinese medicine and other methods accounts for 39. 7%. Conclusion： Although the treatment of cancer pain in China has been made considerable progress, there were still some problems existing in the current studies such as poor analgesic selection, analgesic underdosing, absence of well -publicized work, and weakness of theoretical research.

关 键 词：癌痛 治疗 阿片类药物 

分 类 号：R473.72[医药卫生—护理学] R473.73[医药卫生—临床医学]